Drug:
Reaction: NO ADVERSE EVENT
20250101 - 20251231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 25133228 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 202 | 25133229 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 203 | 25133230 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 204 | 25133231 |
US |
||
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 205 | 25133232 |
US |
||
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 206 | 25133238 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 207 | 25133239 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 208 | 25133243 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 209 | 25133245 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 210 | 25133246 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 211 | 25133247 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 212 | 25133248 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 213 | 25133249 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 214 | 25133251 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 215 | 25133252 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 216 | 25133254 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 217 | 25133255 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 218 | 25133256 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 219 | 25133257 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 220 | 25133281 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 221 | 25133282 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 222 | 25133283 |
US |
||
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 223 | 25133284 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 224 | 25133285 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 225 | 25133288 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 226 | 25133289 |
US |
2 | |
Product substitution issue, Product adhesion issue, No adverse event, |
||||
ESTRADIOL, ESTRADIOL, ESTRADIOL, |
||||
| 227 | 25133290 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 228 | 25133292 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 229 | 25133294 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 230 | 25133295 |
US |
2 | |
Wrong technique in device usage process, Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 231 | 25133302 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 232 | 25133306 |
US |
||
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 233 | 25133307 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 234 | 25133308 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 235 | 25133309 |
US |
||
Product substitution issue, Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 236 | 25133310 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 237 | 25133311 |
US |
||
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 238 | 25133312 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
ESTRADIOL, |
||||
| 239 | 25133314 |
US |
2 | |
Needle issue, No adverse event, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 240 | 25133315 |
US |
2 | |
Incorrect dose administered, Liquid product physical issue, No adverse event, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 241 | 25133316 |
US |
16 | 2 |
Incorrect dose administered, Liquid product physical issue, No adverse event, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 242 | 25133317 |
US |
2 | |
Product packaging quantity issue, No adverse event, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 243 | 25133773 |
US |
55 | 2 |
No adverse event, Product storage error, Product use in unapproved indication, |
||||
| 244 | 25133830 |
US |
2 | |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 245 | 25133843 |
US |
2 | |
Off label use, Maternal exposure timing unspecified, No adverse event, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, |
||||
| 246 | 25133845 |
US |
||
Product dose omission issue, Drug delivery system malfunction, No adverse event, |
||||
OMALIZUMAB, |
||||
| 247 | 25133966 |
US |
37 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 248 | 25134078 |
US |
||
Off label use, No adverse event, |
||||
TRASTUZUMAB, |
||||
| 249 | 25134415 |
US |
2 | |
Off label use, No adverse event, |
||||
EMICIZUMAB, |
||||
| 250 | 25134464 |
US |
1 | |
Off label use, No adverse event, |
||||
EMICIZUMAB, |
||||
| 251 | 25135077 |
US |
1 | |
Syringe issue, Needle issue, No adverse event, |
||||
AVACINCAPTAD PEGOL, AVACINCAPTAD PEGOL, |
||||
| 252 | 25135180 |
US |
69 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 253 | 25135435 |
US |
||
Drug ineffective, No adverse event, |
||||
TRIAMCINOLONE ACETONIDE, |
||||
| 254 | 25136050 |
US |
||
Off label use, No adverse event, |
||||
SELINEXOR, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, SULFAMETHOXAZOLE AND TRIMETHOPRIM, TEMOZOLOMIDE, AMLODIPINE BESYLATE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, OLMESARTAN MEDOXOMIL, |
||||
| 255 | 25136484 |
US |
||
Product dose omission issue, No adverse event, |
||||
PEMBROLIZUMAB, |
||||
| 256 | 25136561 |
US |
76 | 2 |
Off label use, No adverse event, |
||||
BEVACIZUMAB, |
||||
| 257 | 25136943 |
US |
1 | 1 |
Expired product administered, No adverse event, |
||||
| 258 | 25137086 |
US |
||
Drug dose omission by device, No adverse event, Device breakage, |
||||
GLUCAGON, |
||||
| 259 | 25126275 |
US |
||
No adverse event, Prescribed overdose, |
||||
VORTIOXETINE, |
||||
| 260 | 25126420 |
US |
2 | |
Product storage error, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 261 | 25126514 |
US |
||
Drug ineffective, No adverse event, |
||||
OCRELIZUMAB, |
||||
| 262 | 25126615 |
US |
21 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 263 | 25126620 |
US |
1 | |
Incorrect dose administered, No adverse event, |
||||
OMALIZUMAB, |
||||
| 264 | 25126624 |
US |
||
Product storage error, No adverse event, |
||||
VEMURAFENIB, |
||||
| 265 | 25126770 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 266 | 25126773 |
US |
1 | |
No adverse event, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 267 | 25126778 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 268 | 25126779 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 269 | 25126780 |
US |
42 | 2 |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 270 | 25126785 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 271 | 25126798 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 272 | 25126803 |
US |
1 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 273 | 25126804 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 274 | 25126816 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 275 | 25126819 |
US |
1 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 276 | 25126826 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 277 | 25126845 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 278 | 25126847 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 279 | 25126855 |
US |
1 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 280 | 25126862 |
US |
1 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 281 | 25126866 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 282 | 25126868 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 283 | 25126874 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 284 | 25126890 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 285 | 25126925 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 286 | 25126962 |
US |
1 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 287 | 25126975 |
US |
1 | |
No adverse event, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 288 | 25127010 |
US |
1 | |
No adverse event, |
||||
BIMEKIZUMAB, TIRZEPATIDE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, |
||||
| 289 | 25127118 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 290 | 25127155 |
US |
1 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 291 | 25127196 |
US |
2 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 292 | 25127225 |
US |
1 | |
No adverse event, |
||||
BIMEKIZUMAB, |
||||
| 293 | 25127302 |
US |
||
Drug dose omission by device, Wrong technique in device usage process, Device difficult to use, Wrong technique in product usage process, Device mechanical issue, No adverse event, |
||||
TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE, |
||||
| 294 | 25127336 |
US |
63 | 1 |
Off label use, No adverse event, |
||||
OCRELIZUMAB, |
||||
| 295 | 25127371 |
US |
43 | 1 |
No adverse event, Accidental underdose, Device use error, Product dose omission issue, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 296 | 25127536 |
US |
||
No adverse event, Suspected counterfeit product, |
||||
LISDEXAMFETAMINE DIMESYLATE, |
||||
| 297 | 25127565 |
US |
2 | |
No adverse event, Incorrect product administration duration, |
||||
| 298 | 25127662 |
US |
71 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 299 | 25127679 |
US |
2 | |
No adverse event, Product use in unapproved indication, Product use issue, Product storage error, |
||||
PRUCALOPRIDE, GABAPENTIN, NIFEDIPINE, |
||||
| 300 | 25127968 |
US |
1 | |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28